Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Generics Industry Group Gets New Board Chair, Begins Search For New CEO In Earnest

Executive Summary

Christine Baeder’s departure from Teva means transition at the Association for Accessible Medicines’ board of directors as well; Sandoz’s Keren Haruvi becomes chair. The group also started looking for a new permanent CEO to replace Dan Leonard, who left AAM in December 2022.

You may also be interested in...



Off-Patent Personnel Moves In 2023 Reflect Growing Interest In Innovator Space

Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.

US Health And Wellness Executive Moves: Apotex, Thorne, Hain Celestial, Roundhouse Provisions

Christine Baeder, former COO for US generics and biosimilars at Teva, heads OTC and Rx drug manufacturer Apotex in the US; Thorne CEO Paul Jacobson will lead Thorne Ventures focused on innovation and wellness breakthroughs; Amber Jefferson is Hain Celestial’s chief people officer; Roundhouse Provisions brand’s spokesman for its Morning Kick supplement is action film and TV actor Chuck Norris.

Who’s Hired? Teva’s Baeder Takes Lead At Apotex In US

Shortly after departing from her role as Teva’s COO for US generics and biosimilars, Christine Baeder has been named as president of Apotex in the US. Meanwhile, Coherus Biosciences has announced a CFO transition and Amgen has made executive appointments to “accelerate innovation”.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153161

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel